ReviewMolecular biology reports2026
Kinetics and mechanisms in lipopolysaccharide-induced neuroinflammation: a framework for phytochemicals screening.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroinflammation is an innate immune response of the central nervous system in which microglia, astrocytes and neuronal stress pathways regulate the production of cytokines, inflammatory enzymes and redox mediators. Among experimental paradigms, lipopolysaccharide (LPS) provides a stimulus for probing inflammatory signalling and for evaluation of phytochemicals. However, heterogeneity in LPS provenance, chemotype, purification grade, dose, route, exposure duration and endpoint timing compromises cross-study comparability, mechanistic attribution and translational interpretation. This review synthesises evidence from in vitro and in vivo LPS-induced neuroinflammation models used for phytochemical screening and proposes a kinetics- and mechanism-informed framework for experimental design. In vitro, murine microglial systems predominate, particularly BV-2, N9 and primary microglia, with complementary use of astroglia, neuronal and human myeloid or microglia-like platforms. LPS concentrations range from 100 ng/mL to 1 µg/mL, with signalling activation occurring within minutes to hours and inflammatory phenotypes typically assessed at 24-48 h. Frequently used pharmacodynamic readouts include tumour necrosis factor-α, interleukin-1β, interleukin-6, inducible nitric oxide synthase/nitric oxide, cyclooxygenase-2/prostaglandin E2, reactive oxygen species, glial activation markers and viability indices, combined with mechanistic interrogation of NF-κB, MAPK, PI3K-Akt, Nrf2-HO-1 and NLRP3-associated pathways. In vivo, repeated intraperitoneal LPS administration predominates in rodent models, whereas intracerebroventricular and zebrafish models provide complementary spatial and kinetic insights. Overall, LPS challenge should be interpreted as a controlled inflammatory trigger rather than a disease-equivalent surrogate. Rigorous LPS reporting, closer alignment of endpoints with inflammatory kinetics, and multi-endpoint validation across models should strengthen mechanistic inference and support translational evaluation of phytochemical leads.
Indexed as
Identifiers
42848270What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.